McKenna's Pharmacology for Nursing, 2e

973

Index

contraindications and cautions, 195, 197 drug–drug interactions, 198

dopaminergic agents, 372, 374–378 adverse effects, 376 care considerations, 377 contraindications and cautions, 376 drug–drug interactions, 376 pharmacokinetics, 376 therapeutic actions and indications, 374, 376 older adults, 375 Parkinson disease and parkinsonism, 372, 373–374 pathophysiology, 373 treatment, 374 Antiplatelet agents, 750, 751, 755–756, 758–759 adverse effects, 758–759 care considerations, 759 contraindications and cautions, 758 drug–drug interactions, 759 pharmacokinetics, 758 therapeutic actions and indications, 758 Antiprotozoal agents, 163–176 adults, 164 adverse effects, 173 antimalarials, 163, 166–170 adverse effects, 168–169 care considerations, 169–170 combination drugs, 168 contraindications and cautions, 168 cultural considerations, 169 drug–drug interactions, 169 pharmacokinetics, 167–168 therapeutic actions and indications, 166–167 care considerations, 174 children, 164 contraindications and cautions, 172–173 drug–drug interactions, 173–174 malaria, 163, 164–166 life cycle of Plasmodium , 165–166 miscellaneous protozoal infections, 170–172 agents for, 172–174 amoebiasis, 163, 170–171 care considerations, 174 cinchonism, 163 giardiasis, 163, 172 leishmaniasis, 163, 171 Pneumocystis carinii pneumonia, 163, 172 trichomoniasis, 163, 172 trypanosomiasis, 163, 172 older adults, 164 pharmacokinetics, 172 therapeutic actions and indications, 172 Antipsychotic/neuroleptic drugs, 334, 336–342 adverse effects, 341 care considerations, 342 contraindications and cautions, 340 critical thinking scenario, 343–344 cultural considerations, 340 drug–drug interactions, 341 pharmacokinetics, 339 therapeutic actions and indications, 339

Antipyretic, 240, 241 Antirheumatic drugs, 253–255 adverse effects, 254

pharmacokinetics, 195 protective drugs, 198 therapeutic actions and indications, 195 antimetabolites, 190, 200–204 adverse effects, 203 care considerations, 204 contraindications and cautions, 203 drug–drug interactions, 204 pharmacokinetics, 203 therapeutic actions and indications, 200, 202 antineoplastic antibiotics, 205–208 adverse effects, 207 care considerations, 208 contraindications and cautions, 207 drug–drug interactions, 207 pharmacokinetics, 207 therapeutic actions and indications, 205 breast cancer, 217–218 cancer, 190–192 causes, 192 types of, 192 cancer cell-specific agents, 191, 218–220 care considerations, 222 protein tyrosine kinase inhibitors, 218, 220 cell kill theory, 193 children, 194 hormones and hormone modulators, 191, 212–216 adverse effects, 215 care considerations, 216 contraindications and cautions, 212 drug–drug interactions, 215 pharmacokinetics, 212 therapeutic actions and indications, 212 miscellaneous agents, 191, 222–223 mitotic inhibitors, 191, 209–212 adverse effects, 210 care considerations, 211–212 contraindications and cautions, 210 drug–drug interactions, 210–211 pharmacokinetics, 210 therapeutic actions and indications, 210 older adults, 194 sites of action, 193 Antiparkinsonism agents, 372–383 adjunctive agents, 382–383 adults, 375 anticholinergic agents, 379–381 adverse effects, 380 care considerations, 381 contraindications and cautions, 380 drug–drug interactions, 380–381 pharmacokinetics, 380 therapeutic actions and indications, 379–380 children, 375

contraindications and cautions, 254 drug–drug interactions, 254–255 pharmacokinetics, 254 therapeutic actions and indications, 254 Antiseizure agents, 352–369 adults, 354 altered metabolism, 354 children, 354 drugs for treating generalised seizures, 352, 355–363 barbiturates and barbiturate-like drugs, 352, 357, 358–359 benzodiazepines, 352, 357, 359–360 care considerations, 362–363 hydantoins, 352, 356–358 succinimides, 352, 357, 360–361 drugs for treating partial seizures, 352, 365–369 adverse effects, 368 care considerations, 368–369 contraindications and cautions, 367 drug–drug interactions, 368 pharmacokinetics, 367 therapeutic actions and indications, 365, 367 nature of seizures, 353–355 absence seizure, 352, 353, 355

classification, 353–355 generalised, 352, 355

partial, 352, 355 older adults, 354 Antispasmodics, 819, 824–826

Antithrombin III, 754, 756, 759–760 Antithymocyte immune globulin, 286 Antithyroid agents, 552, 557, 560–562 adverse effects, 561

care considerations, 561–562 contraindications and cautions, 560–561 drug–drug interactions, 561 pharmacokinetics, 560

therapeutic actions and indications, 560 Antitoxins, 272, 273, 282, 285, 286–287 Antituberculosis drugs, 118 Antitussives, 842, 843–846 adverse effects, 845 care considerations, 845–846 contraindications and cautions, 845 drug–drug interactions, 845 pharmacokinetics, 845 therapeutic actions and indications, 845 Antivenins, 272, 273, 285, 286–287 Antiviral agents, 126–147 adults, 128 antihepatitis B and C agents, 144–146 adverse effects, 145 care considerations, 146 contraindications and cautions, 145 drug–drug interactions, 145 pharmacokinetics, 144–145 therapeutic actions and indications, 144 children, 128